Addex Therapeutics annual r&d spending
2017
2018
2019
2020
2021
2022
2023
2024
2025
Addex Therapeutics R&D Spending Growth & History (ADXN)
Addex Therapeutics's r&d spending was CHF190,190 for fiscal 2025.
View full Addex Therapeutics company overviewAddex Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | CHF190,190 | −CHF664,115 | −77.74% |
| 2024 | 2024-12-31 | CHF854,305 | −CHF332,387 | −28.01% |
| 2023 | 2023-12-31 | CHF1.2M | −CHF7.1M | −85.61% |
| 2022 | 2022-12-31 | CHF8.2M | −CHF4.6M | −35.80% |
| 2021 | 2021-12-31 | CHF12.8M | CHF2.5M | +23.79% |
| 2020 | 2020-12-31 | CHF10.4M | −CHF2.1M | −16.71% |
| 2019 | 2019-12-31 | CHF12.5M | CHF7.5M | +153.19% |
| 2018 | 2018-12-31 | CHF4.9M | CHF2.3M | +87.10% |
| 2017 | 2017-12-31 | CHF2.6M | — | — |
Addex Therapeutics quarterly r&d spending
Q2.21
Q2.22
Q2.23
Q2.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | CHF9,394 | −CHF23,189 | −71.17% |
| Q4 2025 | 2025-12-31 | CHF3,859 | — | — |
| Q3 2025 | 2025-09-30 | CHF85,256 | — | — |
| Q2 2025 | 2025-06-30 | CHF234,454 | −CHF104,863 | −30.90% |
| Q1 2025 | 2025-03-31 | CHF32,583 | — | — |
| Q2 2024 | 2024-06-30 | CHF339,317 | −CHF1.5M | −81.90% |
| Q2 2023 | 2023-06-30 | CHF1.9M | −CHF3.9M | −67.37% |
| Q2 2022 | 2022-06-30 | CHF5.7M | CHF2.0M | +54.00% |
| Q2 2021 | 2021-06-30 | CHF3.7M | — | — |
Addex Therapeutics r&d spending trends
Over the last five fiscal years, Addex Therapeutics's r&d spending decreased from CHF10.4M to CHF190,190, a change of −CHF10.2M. The latest reported quarter, Q1 2026, shows CHF9,394.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Addex Therapeutics source filings ↗